Otonomy (OTIC) Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Otonomy in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" OTIC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OTIC, but not buy additional shares or sell existing shares.
View OTIC analyst ratings or view top-rated stocks.

2 Wall Street research analysts have issued 12-month target prices for Otonomy's stock. Their OTIC share price forecasts range from $0.50 to $0.50. On average, they predict the company's stock price to reach $0.50 in the next year. This suggests a possible upside of 5,782.4% from the stock's current price.
View analysts price targets for OTIC or view top-rated stocks among Wall Street analysts.

Otonomy, Inc. (NASDAQ:OTIC) released its quarterly earnings results on Wednesday, November, 10th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.19). During the same quarter in the previous year, the company posted ($0.22) EPS.

Based on aggregate information from My MarketBeat watchlists, some companies that other Otonomy investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities (), Sterne Agee CRT (), Robert W. Baird (), Wellington Shields () and Macquarie ().

Otonomy trades on the NASDAQ under the ticker symbol "OTIC."

One share of OTIC stock can currently be purchased for approximately $0.01.

Otonomy (NASDAQ:OTIC) has a market capitalization of $582,479.50 and generates $130,000.00 in revenue each year. The biopharmaceutical company earns $-51,180,000.00 in net income (profit) each year or ($0.77) on an earnings per share basis.

Otonomy's mailing address is 4796 EXECUTIVE DRIVE, SAN DIEGO CA, 92121. The official website for the company is www.otonomy.com. The biopharmaceutical company can be reached via phone at (619) 323-2200, via email at ir@otonomy.com, or via fax at 619-291-9190.